-
4
-
-
0036322892
-
Antipsychotic-related QTc prolongation, torsade de pointes and sudden death
-
Haddad P, Anderson I. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649-71. (Pubitemid 34848372)
-
(2002)
Drugs
, vol.62
, Issue.11
, pp. 1649-1671
-
-
Haddad, P.M.1
Anderson, I.M.2
-
5
-
-
33645219292
-
Antipsychotikainduzierte QT-Verlängerung
-
Haverkamp H, Deuschle M. Antipsychotikainduzierte QT-Verlängerung. Nervenarzt 2006;77:276-88.
-
(2006)
Nervenarzt
, vol.77
, pp. 276-288
-
-
Haverkamp, H.1
Deuschle, M.2
-
6
-
-
0034917323
-
Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: A call for consensus
-
DOI 10.1007/s002280100290
-
DePonti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001;57:185-209. (Pubitemid 32662464)
-
(2001)
European Journal of Clinical Pharmacology
, vol.57
, Issue.3
, pp. 185-209
-
-
De Ponti, F.1
Poluzzi, E.2
Montanaro, N.3
-
7
-
-
82155164409
-
Psychopharmakaassoziierte QTc-Intervall-Verlängerung und Torsade de pointes
-
Wenzel-Seifert K, Wittmann M, Haen E. Psychopharmakaassoziierte QTc-Intervall-Verlängerung und Torsade de pointes. Dtsch Arztebl 2011;108:687-93.
-
(2011)
Dtsch Arztebl
, vol.108
, pp. 687-693
-
-
Wenzel-Seifert, K.1
Wittmann, M.2
Haen, E.3
-
8
-
-
41749091855
-
Medikamentös induzierte Verlängerung des QT-Intervalls
-
Altmann D, Eggmann U, Ammann P. Medikamentös induzierte Verlängerung des QT-Intervalls. Wien Klin Wochenschr 2008;120:128-35.
-
(2008)
Wien Klin Wochenschr
, vol.120
, pp. 128-135
-
-
Altmann, D.1
Eggmann, U.2
Ammann, P.3
-
9
-
-
0037070199
-
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents
-
DOI 10.1016/S0014-5793(01)03320-8, PII S0014579301033208
-
Witchel H, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular calcium currents. FEBS Lett 2002;512:59-66. (Pubitemid 34164451)
-
(2002)
FEBS Letters
, vol.512
, Issue.1-3
, pp. 59-66
-
-
Witchel, H.J.1
Pabbathi, V.K.2
Hofmann, G.3
Paul, A.A.4
Hancox, J.C.5
-
11
-
-
78049442306
-
Torsades de pointes episodes under treatment with selective serotonin reuptake inhibitors
-
Wenzel-Seifert K, Wittmann M, Haen E. Torsades de pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry 2010;43:279-81.
-
(2010)
Pharmacopsychiatry
, vol.43
, pp. 279-281
-
-
Wenzel-Seifert, K.1
Wittmann, M.2
Haen, E.3
-
12
-
-
84856783531
-
-
FDA-2006-4254s-06Jones-Citalopram 16.11
-
Jones M. Review Update: QT-Prolongation with Citalopram and Escitalopram. US Food and Drug Administration (FDA). FDA-2006-4254s-06Jones-Citalopram (16.11.2006). http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4254s-06-Jones- Citalopram.ppt.
-
(2006)
Review Update: QT-Prolongation with Citalopram and Escitalopram
-
-
Jones, M.1
-
13
-
-
0036094878
-
Psychotropic drugs and the ECG: Focus on the QTc interval
-
DOI 10.1517/14656566.3.5.479
-
Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Experts Opin Pharmacother 2002;3:479-98. (Pubitemid 34520859)
-
(2002)
Expert Opinion on Pharmacotherapy
, vol.3
, Issue.5
, pp. 479-498
-
-
Goodnick, P.J.1
Jerry, J.2
Parra, F.3
-
15
-
-
84857367918
-
Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged women: A case report and literature review
-
Im Druck, doi:10.1016/j.genhosp-psych.2011.10.005
-
Tseng P, et al. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged women: a case report and literature review. Gen Hosp Psychiatry. Im Druck, 2011. doi:10.1016/j.genhosp- psych.2011.10.005.
-
(2011)
Gen Hosp Psychiatry
-
-
Tseng, P.1
-
16
-
-
46349105061
-
Drug-induced torsades de pointes: A review of the Swedish pharmacovigilance database
-
Astrom-Lilja C, et al. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf 2008;17:587-92.
-
(2008)
Pharmacoepidemiol Drug Saf
, vol.17
, pp. 587-592
-
-
Astrom-Lilja, C.1
-
17
-
-
65949096013
-
Drug-induced torsades de pointes: Data mining of the public version of the FDA Adverse Event Reporting System (AERS)
-
Poluzzi E, et al. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf 2009;18:512-518.
-
(2009)
Pharmacoepidemiol Drug Saf
, vol.18
, pp. 512-518
-
-
Poluzzi, E.1
-
19
-
-
84856807340
-
Haloperidol nicht mehr intravenös?
-
Hiesinger L, et al. Haloperidol nicht mehr intravenös? Neurotransmitter 2010;9:22-3.
-
(2010)
Neurotransmitter
, vol.9
, pp. 22-23
-
-
Hiesinger, L.1
-
20
-
-
79953290888
-
Citalopram-induced long QT syndrome and torsade de pointes: Role for committant therapies and illnesses
-
De Gregorio C, et al. Citalopram-induced long QT syndrome and torsade de pointes: role for committant therapies and illnesses. Int J Cardiol 2009;148:226-8.
-
(2009)
Int J Cardiol
, vol.148
, pp. 226-228
-
-
De Gregorio, C.1
-
21
-
-
0004282841
-
Psychopharmaka
-
Schwabe U, Paffrath D (Hrsg.). Berlin: Springer
-
Lohse MJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D (Hrsg.). Arzneiverordnungs-Report 2010: Aktuelle Daten, Kosten, Trends und Kommentare, Berlin: Springer, 2010:797-841.
-
(2010)
Arzneiverordnungs-Report 2010: Aktuelle Daten, Kosten, Trends und Kommentare
, pp. 797-841
-
-
Lohse, M.J.1
Müller-Oerlinghausen, B.2
-
22
-
-
0034712552
-
QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
-
Reilly J, Ayes S, Ferrier I. QTc interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;335:1048-52. (Pubitemid 30162807)
-
(2000)
Lancet
, vol.355
, Issue.9209
, pp. 1048-1052
-
-
Reilly, J.G.1
Ayis, S.A.2
Ferrier, I.N.3
Jones, S.J.4
Thomas, S.H.L.5
-
24
-
-
24744440356
-
Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen zur Therapieleitung
-
Haen E, Bedeutung der klinisch-pharmakologischen Befundung von Wirkstoffkonzentrationsmessungen zur Therapieleitung. Psychopharmakotherapie 2005;12:138-43.
-
(2005)
Psychopharmakotherapie
, vol.12
, pp. 138-143
-
-
Haen, E.1
-
25
-
-
44149103099
-
Wirkstoffkonzentrationsbestimmungen zur Therapieleitung - Ergänzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche
-
Haen E, et al. Wirkstoffkonzentrationsbestimmungen zur Therapieleitung - Ergänzung therapeutischer Referenzbereiche durch dosisbezogene Referenzbereiche. Nervenarzt 2008;79:558-66.
-
(2008)
Nervenarzt
, vol.79
, pp. 558-566
-
-
Haen, E.1
-
26
-
-
80053383810
-
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011
-
Hiemke C, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 2011;44:195-235.
-
(2011)
Pharmacopsychiatry
, vol.44
, pp. 195-235
-
-
Hiemke, C.1
|